Drug Profile
Research programme: acetyl-CoA synthetase 2 inhibitors - Peloton Therapeutics
Alternative Names: PT 1403Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Peloton Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Acetate-CoA ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Cancer in USA
- 30 Jul 2019 Peloton Therapeutics has been acquired by Merck & Co
- 06 Dec 2016 Early research in Cancer in USA (unspecified route)